My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

Another male patient with blood cancer had been administered approximately twice the prescribed dose of Fludarabine, another chemotherapy drug, for three consecutive days. In early March ...

Here are the critical medicines in short supply in the EU, according to the latest available information from the EMA and ...

Q4 2024 Earnings Call Transcript March 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.

The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic ...

Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab.

Fate Therapeutics FATE reported a loss of 31 cents per share (excluding impairment loss) in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 44 cents. The company ...

Acute myelogenous leukemia (AML) is seen in this stock image. Duke researchers have discovered a new combination of drugs that is more effective than chemotherapy at killing acute myeloid leukemia ...